Share chart Adynxx Inc
Extended chart
Simple chart
About
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
| ISIN |
US00784D1037 |
| Industry |
Biotechnology |
| Sector |
Health Care |
| Валюта |
usd |
| Валюта отчета |
usd |
| Сайт |
https://www.adynxx.com
|
| Change price per day: |
0% (0.0001) |
| Change price per week: |
0% (0.0001) |
| Change price per month: |
0% (0.0001) |
| Change price per 3 month: |
0% (0.0001) |
| Change price per half year: |
0% (0.0001) |
| Change price per year: |
0% (0.0001) |
| Change price per 3 year: |
-99.76% (0.0411) |
| Change price per 5 year: |
-100% (2.48) |
| Change price per 10 year: |
0% (0.0001) |
| Change price per year to date: |
0% (0.0001) |
|
|
Underestimation
| Title |
Value |
Grade |
| P/S |
0 |
0 |
| P/BV |
0 |
0 |
| P/E |
0 |
0 |
| EV/EBITDA |
0 |
0 |
| Total: |
|
2.5 |
|
Efficiency
| Title |
Value |
Grade |
| ROA, % |
0 |
0 |
| ROE, % |
0 |
0 |
| Total: |
|
0 |
|
|
|
Dividends
| Title |
Value |
Grade |
| Div yield, % |
0 |
0 |
| DSI |
0.5 |
5 |
| Total: |
|
2.35 |
|
Debt
| Title |
Value |
Grade |
| Debt/EBITDA |
0 |
10 |
| Total: |
|
10 |
|
Growth impulse
| Title |
Value |
Grade |
| Yield Revenue, % |
-53.7 |
0 |
| Yield Ebitda, % |
-93.16 |
0 |
| Yield EPS, % |
-95.64 |
0 |
| Total: |
|
0 |
|
| Head |
Job title |
Payment |
Year of birth |
| Mr. Richard Orr Esq., J.D. |
President, CEO, Principal Financial Officer & Director |
|
1961 (64 years) |
| Dr. Julien Mamet Ph.D. |
Founder, Chief Scientific Officer & Director |
|
1976 (49 years) |
| Mr. William Martin |
Executive Vice President of Corporate Development & Operations |
|
|
| Ms. Dina Gonzalez |
Principal Accounting Officer & Senior VP of Finance |
|
|
| Ms. Kimberley Hebert |
Senior Director of Clinical Operations |
|
|
